- Home
- COEP vs RFL Comparison
COEP vs RFL Comparison
Compare COEP & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COEP | RFL |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 61.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | COEP | RFL |
|---|---|---|
| Price | $11.69 | $1.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.1K | ★ 77.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $6.32 | $1.12 |
| 52 Week High | $21.41 | $3.19 |
Technical Indicators
Market Signals| Indicator | COEP | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 61.62 |
| Support Level | $10.74 | $1.30 |
| Resistance Level | $15.98 | $1.44 |
| Average True Range (ATR) | 0.70 | 0.07 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 25.00 | 47.49 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.